Stenotrophomonas maltophilia: Difference between revisions
From IDWiki
Stenotrophomonas maltophilia
(→) |
m (Text replacement - "[[Cellular shape::" to "[[Shape::") |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
===Microbiology=== |
===Microbiology=== |
||
| − | *Aerobic, non-fermentive, [[Catalase |
+ | *Aerobic, non-fermentive, catalase [[Catalase::positive]], oxidase [[Oxidase::negative]], [[Stain::Gram-negative]] [[Shape::bacillus]] |
*Multiple mechanisms of resistance |
*Multiple mechanisms of resistance |
||
**RND, MfsA, and Sme-related efflux pumps |
**RND, MfsA, and Sme-related efflux pumps |
||
| Line 19: | Line 19: | ||
*Therapy should be guided by antimicrobial susceptibility testing |
*Therapy should be guided by antimicrobial susceptibility testing |
||
*Antistenotrophomonal antibiotics: |
*Antistenotrophomonal antibiotics: |
||
| − | **[[Is treated by::TMP-SMX]] (preferred agent, if susceptible) |
+ | **[[Is treated by::TMP-SMX]] 15 mg/kg split q8h (preferred agent, if susceptible) |
**[[Is treated by::Fluoroquinolones]], including [[Is treated by::moxifloxacin]], [[Is treated by::levofloxacin]], and [[Is treated by::ciprofloxacin]] (though develops resistance quickly on monotherapy) |
**[[Is treated by::Fluoroquinolones]], including [[Is treated by::moxifloxacin]], [[Is treated by::levofloxacin]], and [[Is treated by::ciprofloxacin]] (though develops resistance quickly on monotherapy) |
||
**[[Is treated by::Minocycline]], [[Is treated by::doxycycline]], and [[Is treated by::tigecycline]] |
**[[Is treated by::Minocycline]], [[Is treated by::doxycycline]], and [[Is treated by::tigecycline]] |
||
Latest revision as of 14:24, 13 October 2020
Background
Microbiology
- Aerobic, non-fermentive, catalase positive, oxidase negative, Gram-negative bacillus
- Multiple mechanisms of resistance
- RND, MfsA, and Sme-related efflux pumps
- Sul or dfrA genes (TMP-SMX resistance)
- β-lactamases
- Aminoglycoside-modifying enzymes
Clinical Manifestations
- Nosocomial infections with high mortality and high antibiotic resistance
Management
- Limited antibiotic options
- Therapy should be guided by antimicrobial susceptibility testing
- Antistenotrophomonal antibiotics:
- TMP-SMX 15 mg/kg split q8h (preferred agent, if susceptible)
- Fluoroquinolones, including moxifloxacin, levofloxacin, and ciprofloxacin (though develops resistance quickly on monotherapy)
- Minocycline, doxycycline, and tigecycline
- Ticarcillin-clavulanate and ampicillin-sulbactam
- Ceftazidime and ceftazidime-avibactam
- Colistin, though high rates of resistance
- Possibly ceftriaxone
